<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Fertil Steril</journal-id><journal-id journal-id-type="iso-abbrev">Int J Fertil Steril</journal-id><journal-id journal-id-type="publisher-id">Royan Institute</journal-id><journal-title-group><journal-title>International Journal of Fertility &#x00026; Sterility</journal-title></journal-title-group><issn pub-type="ppub">2008-076X</issn><issn pub-type="epub">2008-0778</issn><publisher><publisher-name>Royan Institute</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">36029050</article-id><article-id pub-id-type="pmc">PMC9421263</article-id><article-id pub-id-type="other">Int-J-Fertil-Steril-16-156</article-id><article-id pub-id-type="doi">10.22074/IJFS.2021.532258.1140</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject><subj-group><subject>Andrology</subject><subject>Gynecology and Female Infertility</subject></subj-group></subj-group></article-categories><title-group><article-title>Evaluation of Azoospermic Patients to Distinguish Obstructive
from Non-Obstructive Azoospermia, and Necessity of
Diagnostic Testis Biopsy: A Retrospective Study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Shamohammadi</surname><given-names>Iman</given-names></name><degrees>M.D</degrees><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Sadighi Gilani</surname><given-names>Mohammad Ali</given-names></name><degrees>M.D</degrees><xref rid="A1" ref-type="aff">1</xref><xref rid="A3" ref-type="aff">3</xref><xref rid="cor1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Kazemeyni</surname><given-names>Seyed Mohammad</given-names></name><degrees>M.D</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Hasanzadeh</surname><given-names>Tara</given-names></name><degrees>M.D</degrees><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Taqi Dizaj</surname><given-names>Ahmad Vosough</given-names></name><degrees>M.D</degrees><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Dizavi</surname><given-names>Alireza</given-names></name><degrees>M.Sc</degrees><xref rid="A3" ref-type="aff">3</xref></contrib><aff id="A1"><label>1</label>Department of Urology, Shariati Hospital, Tehran University of Medical Science, Tehran, Iran</aff><aff id="A2"><label>2</label>Department of Urology, Nemazee Hospital, Shiraz University of Medical Science, Shiraz, Iran</aff><aff id="A3"><label>3</label>Department of Reproductive Imaging, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedi-
cine, ACECR, Tehran, Iran</aff></contrib-group><author-notes><corresp id="cor1">
<label>*Corresponding Address: </label>
<addr-line>P.O.Box: 1411713135</addr-line>
<addr-line>Department of Urology</addr-line>
<addr-line>Shariati Hospital</addr-line>
<institution>Tehran University of Medical Science</institution>
<addr-line>Tehran</addr-line>
<country>Iran</country>
Email:<email>masadighi@gmail.com</email>
</corresp></author-notes><pub-date pub-type="ppub"><season>Jul-Sep</season><year>2022</year></pub-date><pub-date pub-type="epub"><day>21</day><month>8</month><year>2022</year></pub-date><volume>16</volume><issue>3</issue><fpage>156</fpage><lpage>161</lpage><history><date date-type="received"><day>16</day><month>6</month><year>2021</year></date><date date-type="accepted"><day>29</day><month>11</month><year>2021</year></date></history><permissions><copyright-statement>Any use, distribution, reproduction or abstract of this publication in any medium,
with the exception of commercial purposes, is permitted provided the original work is properly cited.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/3.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative
Commons Attribution Non-Commercial 3.0 (CC BY-NC 3.0) License, which permits
unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original
work is properly cited. </license-p></license></permissions><abstract><sec><title>Background</title><p>Accurate etiology of azoospermia is required for optimal management of patients. The aim of this
study was the determination of serum hormonal levels and testicular long axis cut off points to distinguish obstructive
azoospermia (OA) from non-OA (NOA) in Iranian patients as well as the evaluation of the necessity of diagnostic
testis biopsy in azoospermic patients.</p></sec><sec><title>Materials and Methods</title><p>In this retrospective study, data of 471 azoospermic patients such as history and physi-
cal examination, serum hormonal level, semen fluid parameter, and testicular long axis based on ultrasound were
evaluated from 2016 to 2020. All patients were examined by a single urologist and underwent a diagnostic testis
biopsy for a definite diagnosis. The diagnostic parameters were analyzed using Statistical Package for the Social
Sciences (SPSS) version 16 with t test and chi-square test and receiver operating characteristic (ROC) curves to
distinguish NOA from OA.</p></sec><sec><title>Results</title><p>A total of 127 patients with OA and 284 with NOA were included in this study. The mean serum testosterone
level was significantly higher in OA than NOA (4.2 vs. 3.4 ng/ml), whereas the mean serum follicular stimulating hor-
mone (FSH, 5.3 vs. 19.1 mIU/ml) and luteinizing hormone (LH, 5.3 vs. 11 mIU/ml) were lower in OA. ROC curve analy-
sis showed that FSH and testicular long axis were the best diagnostic predictors. Using a combination of serum FSH (8.9
mIU/ml) and testicular long axis (39 mm), the positive predictive value for NOA was 97.02% and for OA was 78.8%.</p></sec><sec><title>Conclusion</title><p>Combination of serum FSH higher than 8.9 mIU/ml and testicular long axis lower than 39 mm were
strong predictors to distinguish NOA from OA in Iranian participants in this study. In addition, diagnostic testicular
biopsy seems to be necessary for patients with OA and NOA characteristics.</p></sec></abstract><kwd-group><kwd>Biopsy</kwd><kwd>Nonobstructive Azoospermia</kwd><kwd>Obstructive Azoospermia</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>Citation</meta-name><meta-value>Shamohammadi I, Sadighi Gilani MA, Kazemeyni SM, Hasanzadeh T, Vosough Taqi Dizaj A, Dizavi A. Evaluation of azoospermic patients to distinguish
obstructive from non-obstructive azoospermia, and necessity of diagnostic testis biopsy: a retrospective study. Int J Fertil Steril. 2022; 16(3): 156-161.
doi: 10.22074/IJFS.2021.532258.1140.
This open-access article has been published under the terms of the Creative Commons Attribution Non-Commercial 3.0 (CC BY-NC 3.0).</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Infertility is one of the major medical problems in
the world (<xref rid="B1" ref-type="bibr">1</xref>). The prevalence of male infertility is
unknown due to conflicting reports (<xref rid="B2" ref-type="bibr">2</xref>). One cause of
male infertility is azoospermia, which is defined as a
lack of sperm in semen analysis after centrifugation
(<xref rid="B3" ref-type="bibr">3</xref>) and is confirmed by two consecutive semen tests
(<xref rid="B4" ref-type="bibr">4</xref>). The prevalence of azoospermia is about 1 % in the
general male population (<xref rid="B5" ref-type="bibr">5</xref>) and approximately 10%
of infertile males (<xref rid="B6" ref-type="bibr">6</xref>). Azoospermia divides into two
types, including obstructive azoospermia (OA) and
non-OA (NOA) (<xref rid="B7" ref-type="bibr">7</xref>). About 40% of the azoospermic
patient are in the OA group, which occurs secondary
to a physical obstruction in sperm transfer from the
testis to the urethra (<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>). About 60% of azoospermic
patients are in the NOA group, which occurs secondary
to testicular failure in sperm production (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>).
Accurate etiology of azoospermia is required for
optimal management of patients (<xref rid="B12" ref-type="bibr">12</xref>). Sperm retrieval
in NOA is done by microdissection testicular sperm
extraction (mTESE) (<xref rid="B13" ref-type="bibr">13</xref>). OA is usually corrected by
reconstructive microsurgery (<xref rid="B14" ref-type="bibr">14</xref>). There are several
clinical and laboratory differences between OA and
NOA that reduce the role of diagnostic testis biopsy (<xref rid="B15" ref-type="bibr">15</xref>). According to studies, a combination of testicular
long axis with a cutoff point of 4.6 cm and serum FSH
with a cutoff point of 7.6 mlU/mL could predict the type
of azoospermia with high sensitivity and specificity
(<xref rid="B16" ref-type="bibr">16</xref>). However, those levels of the published data
regarding the differentiation between OA and NOA
weren&#x02019;t applicable in our population. Therefore, we
decided to conduct a study with the aim of determining
serum hormonal level and testicular long axis cut off
points to distinguish OA from NOA in Iranian patients.
The necessity of diagnostic testis biopsy azoospermic
patients was also evaluated in this study.</p></sec><sec sec-type="materials-methods"><title>Materials and Methods</title><sec><title>Patients</title><p>In this retrospective study, from 2016 to 2020, a total
of 471 azoospermic patients were evaluated. The present
study is approved by the Ethics Committee of Tehran
University of Medical Sciences with the code of ethics
(IR.TUMS.MEDICINE.REC.1399.1005). All male
participants in this study were examined by a single
urologist and underwent a diagnostic testes biopsy
as well as testis ultrasound by a single radiologist.
27 patients with a diagnosis of Klinefelter syndrome,
9 patients with a diagnosis of hypogonadotropic
hypogonadism and 24 patients due to incomplete file
information were excluded from this study. Finally,
411 azoospermic patients were evaluated, including
284 NOA and 127 OA. Data of patients include age,
height, weight, history of herniorrhaphy, history of
vasectomy, history of varicocelectomy, history of
epididymo-orchitis or urinary tract infection, history
of cryptorchidism and orchiopexy, testicular volume
estimation with orchidometer, palpation of the vas,
testicular long axis based on ultrasound, serum FSH
level, serum LH level, serum testosterone level, semen
fluid analysis report for fructose, pH and volume, final
testicular pathology report and microscopic report
during testis biopsy were extracted from the files and
were entered into a checklist.</p></sec><sec><title>Statistical analysis</title><p>The collected data was analyzed using Statistical
Package for the Social Sciences (SPSS, SPSS Inc.,
Chicago, IL, USA) version 16, with t-test and chi-square
test. P&#x0003c;0.05 were considered statistically significant.
The receiver operating characteristic (ROC) curve
(<xref rid="B17" ref-type="bibr">17</xref>) was also used to determine the appropriate cutoff
points for the hormonal profile and testicular long axis
to distinguish NOA from OA. Accuracy was assessed by
the area under the ROC curve (AUC), and results were
considered to be excellent (AUC 0.9-1), good (AUC 0.8-
0.9), fair (AUC 0.7-0.8), poor (AUC 0.6-0.7) and failed
(AUC 0.5-0.6).
</p></sec></sec><sec sec-type="results"><title>Results</title><p>In this study, 411 azoospermic patients were analyzed.
All of them underwent diagnostic testis biopsy. 284
cases (69.1%) were NOA and 127 cases (30.9%) were
OA. Demographic information, history, and physical
examination, testicular long axis based on ultrasound,
hormonal profile, and semen fluid analysis are compared
between NOA and OA in Table 1.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Comparison of demographic and testis ultrasound and laboratory
data between OA and NOA
</p></caption><table frame="hsides" rules="groups"><tbody><tr><th colspan="4" rowspan="1">
<hr/>
</th></tr><tr><th rowspan="1" colspan="1">Baseline characteristics of patients</th><th rowspan="1" colspan="1">OA</th><th rowspan="1" colspan="1">NOA</th><th rowspan="1" colspan="1">P value<sup>*</sup></th></tr><tr><th colspan="4" rowspan="1">
<hr/>
</th></tr><tr><td align="left" rowspan="1" colspan="1">Patients (%)</td><td rowspan="1" colspan="1">127 (30.9)</td><td rowspan="1" colspan="1">284 (69.1)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Age (Y)</td><td rowspan="1" colspan="1">33.10 &#x000b1; 6.22</td><td rowspan="1" colspan="1">31.91 &#x000b1; 5.03</td><td rowspan="1" colspan="1">0.06</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td rowspan="1" colspan="1">26.70 &#x000b1; 3.80</td><td rowspan="1" colspan="1">26.17 &#x000b1; 4.80</td><td rowspan="1" colspan="1">0.24</td></tr><tr><td align="left" rowspan="1" colspan="1">Genitourinary tractinfection </td><td rowspan="1" colspan="1">1 (0.7)</td><td rowspan="1" colspan="1">4 (1.4)</td><td rowspan="1" colspan="1">0.17</td></tr><tr><td align="left" rowspan="1" colspan="1">Epididymitis history </td><td rowspan="1" colspan="1">5 (3.9)</td><td rowspan="1" colspan="1">3 (1.1)</td><td rowspan="1" colspan="1">0.051</td></tr><tr><td align="left" rowspan="1" colspan="1">Unilateral UDT and orchiopexy </td><td rowspan="1" colspan="1">8 (6.2)</td><td rowspan="1" colspan="1">20 (7)</td><td rowspan="1" colspan="1">0.53</td></tr><tr><td align="left" rowspan="1" colspan="1">Bilateral UDT and orchiopexy</td><td rowspan="1" colspan="1">5 (3.9)</td><td rowspan="1" colspan="1">12 (4.2)</td><td rowspan="1" colspan="1">0.57</td></tr><tr><td align="left" rowspan="1" colspan="1">Unilateral herniorrahphy</td><td rowspan="1" colspan="1">10 (7.9)</td><td rowspan="1" colspan="1">18 (6.3)</td><td rowspan="1" colspan="1">0.57</td></tr><tr><td align="left" rowspan="1" colspan="1">Bilateral herniorrahphy</td><td rowspan="1" colspan="1">4 (3.1)</td><td rowspan="1" colspan="1">6 (2.1)</td><td rowspan="1" colspan="1">0.53</td></tr><tr><td align="left" rowspan="1" colspan="1">Unilateral varicocelectomy</td><td rowspan="1" colspan="1">15 (11.8)</td><td rowspan="1" colspan="1">33 (11.6)</td><td rowspan="1" colspan="1">0.96</td></tr><tr><td align="left" rowspan="1" colspan="1">Bilateral varicocelectomy</td><td rowspan="1" colspan="1">7 (5.5)</td><td rowspan="1" colspan="1">11 (3.9)</td><td rowspan="1" colspan="1">0.45</td></tr><tr><td align="left" rowspan="1" colspan="1">Bilateral vasectomy</td><td rowspan="1" colspan="1">4 (3.1)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" rowspan="1" colspan="1">At least one palpable vas </td><td rowspan="1" colspan="1">103 (81.1)</td><td rowspan="1" colspan="1">283 (99.6)</td><td rowspan="1" colspan="1">0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Testis volume in P/E (ml)</td><td rowspan="1" colspan="1">19.06 &#x000b1; 4.50</td><td rowspan="1" colspan="1">10.50 &#x000b1; 5.45</td><td rowspan="1" colspan="1">0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Testis length in P/E (cm)</td><td rowspan="1" colspan="1">3.89 &#x000b1; 0.38</td><td rowspan="1" colspan="1">2.78 &#x000b1; 1.13</td><td rowspan="1" colspan="1">0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Testis longitudinal axis in ultrasound (mm)</td><td rowspan="1" colspan="1">39.83 &#x000b1; 3.36</td><td rowspan="1" colspan="1">33.05 &#x000b1; 6.00</td><td rowspan="1" colspan="1">0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Volume of semen fluid (ml)</td><td rowspan="1" colspan="1">1.66 &#x000b1; 1.51</td><td rowspan="1" colspan="1">2.85 &#x000b1; 1.53</td><td rowspan="1" colspan="1">0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">PH of semen fluid</td><td rowspan="1" colspan="1">7.08 &#x000b1; 0.61</td><td rowspan="1" colspan="1">7.72 &#x000b1; 0.23</td><td rowspan="1" colspan="1">0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Fructose of semen fluid (mg/dl)</td><td rowspan="1" colspan="1">77.04 &#x000b1; 114.80</td><td rowspan="1" colspan="1">202.02 &#x000b1; 91.50</td><td rowspan="1" colspan="1">0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Serum LH (mIU/ml)</td><td rowspan="1" colspan="1">5.33 &#x000b1; 3.05</td><td rowspan="1" colspan="1">11.05 &#x000b1; 6.16</td><td rowspan="1" colspan="1">0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Serum FSH(mIU/ml)</td><td rowspan="1" colspan="1">5.30 &#x000b1; 4.11</td><td rowspan="1" colspan="1">19.11 &#x000b1; 10.61</td><td rowspan="1" colspan="1">0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Serum testosterone (ng/ml)</td><td rowspan="1" colspan="1">4.26 &#x000b1; 1.86</td><td rowspan="1" colspan="1">3.40 &#x000b1; 1.75</td><td rowspan="1" colspan="1">0.0001</td></tr><tr><th colspan="4" rowspan="1">
<hr/>
</th></tr></tbody></table><table-wrap-foot><fn><p>Data are presented as mean &#x000b1; SD or n (%). OA; Obstructive azoospermia, NOA; Nonobstructive azoospermia, BMI; Body mass index, UDT; Undescended testis, P/E; Physical
examination, LH; Luteinizing hormone, FSH; Follicular stimulating hormone, and *;
Analysed with t test or chi-square.</p></fn></table-wrap-foot></table-wrap><p>OA patients had a mean age (33.1 years) and BMI
(26.7). NOA patients had a mean age (31.9 years) and
BMI (26.1). There were no significant differences
between the two groups about age, BMI, history of
urinary tract infections and epididymo-orchitis, history
of UDT and orchiopexy, history of varicocelectomy, and
herniorrhaphy (P&#x0003e;0.05). Only 4 out of 127 OA patients
had a history of vasectomy. Clinical examination
findings including at least one palpable vas, testis size,
testis volume, and also the testicular long axis base on ultrasound were significant differences between the
two groups (P&#x0003c;0.05). OA patients had significantly
greater testis size than NOA patients (P&#x0003c;0.05). The
mean serum testosterone level in OA (4.26 ng/ml) was
significantly more than NOA (3.40 ng/ml). The mean
serum FSH level in OA (5.3 mIU/ml) was significantly
lower than NOA (19.11 mIU/ml), and similarly, the
mean serum LH level in OA was significantly lower
than NOA (P&#x0003c;0.05). Semen fluid analysis findings
including volume, pH and fructose in OA were
significantly lower than NOA (P&#x0003c;0.05). ROC curve
analysis was performed to determine cutoff points for
differentiation between OA and NOA. Figure 1 shows
the ROC curve for serum FSH, LH, testosterone level,
and testicular long axis.</p><fig position="float" id="F1"><label>Fig 1</label><caption><p>ROC curve for serum hormonal level and testicular long axis. Testis
length (0.85), FSH (0.92), LH (0.81), and testosterone (0.65). ROC; Receiver
operating characteristic, FSH; Follicular stimulating hormone, and LH;
Luteinizing hormone.</p></caption><graphic xlink:href="Int-J-Fertil-Steril-16-156-g01" position="float"/></fig><p>According to Figure 1, serum FSH with a curved area
(0.92), the testicular long axis with a curved area (0.85)
and serum LH with a curved area (0.81) had excellent
accuracy for differentiating OA from NOA, but serum
testosterone with a curve area (0.64) had poor accuracy for
differentiating OA from NOA. Based on the ROC curve
by determining the cut off point 8.9 mIU/ml for serum
FSH with the sensitivity of 85%, specificity of 77%, the
positive predictive value of 92%, the negative predictive
value of 62%, accuracy of 80%, and determining the cut
off point 39 mm for testicular long axis with the sensitivity
of 83%, specificity of 87%, positive predictive value
93%, the negative predictive value of 70%, accuracy of
84% can differentiate between OA and NOA. According
to Table 2, by combination cut off points of serum FSH
and testicular long axis with the highest accuracy, 69%
of NOA patients had FSH &#x02265;8.9 mIU/ml &#x00026; testicular long
axis &#x0003c;39 mm, and 76% of OA patients had FSH&#x0003c;8.9 mIU/
ml &#x00026; testicular long axis &#x02265;39 mm. These differences were
significant (P&#x0003c;0.05).</p><p>Based on the ROC curve, a combination of serum FSH
level and testicular long axis had sensitivity (88.28%),
specificity (94.17%), positive predictive value (97.02%),
negative predictive value (78.86%) and accuracy
(90.15%) for differentiating NOA from OA. According
to Table 3, we can predict that azoospermic patients with
serum FSH &#x02265;8.9 mIU/ml &#x00026; testicular long axis &#x0003c;39 mm
are in the NOA group (positive predictive value 97.02%),
and azoospermic patients with FSH &#x0003c;8.9 mIU/ml and
testicular long axis &#x02265;39 mm are in OA group (positive
predictive value 78.86%).
</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Combining testis longitudinal axis size and FSH for differentiation
NOA from OA</p></caption><table frame="hsides" rules="groups"><tbody><tr><th colspan="4" rowspan="1">
<hr/>
</th></tr><tr><th rowspan="1" colspan="1">FSH and testis length of patients</th><th rowspan="1" colspan="1">OA</th><th rowspan="1" colspan="1">NOA</th><th rowspan="1" colspan="1">P value<sup>*</sup></th></tr><tr><th colspan="4" rowspan="1">
<hr/>
</th></tr><tr><td align="left" rowspan="1" colspan="1">FSH&#x0003c;8.9 and testis length&#x02265;39 mm</td><td rowspan="1" colspan="1">97 (76.4)</td><td rowspan="1" colspan="1">26 (9.2)</td><td rowspan="1" colspan="1">0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">FSH&#x0003c;8.9 and testis length&#x0003c;39 mm</td><td rowspan="1" colspan="1">11 (8.7)</td><td rowspan="1" colspan="1">40 (14.1)</td><td rowspan="1" colspan="1">0.12</td></tr><tr><td align="left" rowspan="1" colspan="1">FSH&#x02265;8.9 and testis length&#x02265;39 mm</td><td rowspan="1" colspan="1">13 (10.2)</td><td rowspan="1" colspan="1">22 (7.7)</td><td rowspan="1" colspan="1">0.40</td></tr><tr><td align="left" rowspan="1" colspan="1">FSH&#x02265;8.9 and testis length&#x0003c;39 mm</td><td rowspan="1" colspan="1">6 (4.7)</td><td rowspan="1" colspan="1">196 (69)</td><td rowspan="1" colspan="1">0.0001</td></tr><tr><th colspan="4" rowspan="1">
<hr/>
</th></tr></tbody></table><table-wrap-foot><fn><p>Data are presented as n (%). FSH; Follicular stimulating hormone, NOA; Non-obstructive
azoospermia, OA; Obstructive azoospermia, and *; Analysed with chi-square.
</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Positive predicting value for NOA or OA using testicular long axis
and FSH</p></caption><table frame="hsides" rules="groups"><tbody><tr><th colspan="5" rowspan="1">
<hr/>
</th></tr><tr><th rowspan="1" colspan="1">FSH and testis length of patients</th><th rowspan="1" colspan="1">OA</th><th rowspan="1" colspan="1">NOA</th><th rowspan="1" colspan="1">PPV for NOA</th><th rowspan="1" colspan="1">PPV for OA</th></tr><tr><th colspan="5" rowspan="1">
<hr/>
</th></tr><tr><td align="left" rowspan="1" colspan="1">FSH&#x0003c;8.9 and testis length&#x02265;39</td><td rowspan="1" colspan="1">97 (76.4)</td><td rowspan="1" colspan="1">26 (9.2)</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">78.86</td></tr><tr><td align="left" rowspan="1" colspan="1">FSH&#x02265;8.9 and testis length&#x0003c;39</td><td rowspan="1" colspan="1">6 (4.7)</td><td rowspan="1" colspan="1">196 (69)</td><td rowspan="1" colspan="1">97.02</td><td rowspan="1" colspan="1">-</td></tr><tr><th colspan="5" rowspan="1">
<hr/>
</th></tr></tbody></table><table-wrap-foot><fn><p>Data are presented as n (%) or %. NOA; Non obstructive azoospermia, OA; Obstructive
azoospermia, FSH; Follicular stimulating hormone, and PPV; Positive predictive value.
</p></fn></table-wrap-foot></table-wrap><p>The final pathological reports of azoospermic patients are
shown in Table 4. Sertoli cell-only syndrome pattern was the
most common pathology in azoospermic patients (37%).</p><p>According to Table 4, normal spermatogenesis pattern
in the group of azoospermic patients with FSH &#x0003c;8.9 mIU/
ml and testicular long axis &#x02265;39 mm, and Sertoli cell only
syndrome pattern in the group of azoospermic patients
with FSH &#x02265;8.9 mIU/ml and testicular long axis &#x0003c;39
mm were most common pathological reports (P&#x0003c;0.05).
Photomicrographs describing pathological reports are
shown in Figure 2.</p><fig position="float" id="F2"><label>Fig 2</label><caption><p>Photomicrographs pathological reports of testis biopsy. <bold>A. </bold>Normal spermatogenesis,
<bold>B. </bold>Hypo spermatogenesis, <bold>C. </bold>Maturation arrest, <bold>D.
</bold>Sertoli cell only syndrome, <bold>E.</bold> Lydig cell hyperplasia, and <bold>F.
</bold>Mixed pattern (scale bar: 20 &#x000b5;m).</p></caption><graphic xlink:href="Int-J-Fertil-Steril-16-156-g02" position="float"/></fig><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Pathological report of testis biopsy specimen in azoospermic patients</p></caption><table frame="hsides" rules="groups"><tbody><tr><th colspan="6" rowspan="1">
<hr/>
</th></tr><tr><th rowspan="1" colspan="1">Report of pathology</th><th rowspan="1" colspan="1">Azoospermic patients (n=411)</th><th rowspan="1" colspan="1">FSH&#x0003c;8.9 and testis length&#x0003c;39 (n=51)</th><th rowspan="1" colspan="1">FSH&#x0003c;8.9 and testis length&#x02265;39 (n=123)</th><th rowspan="1" colspan="1">FSH&#x02265;8.9 and testis length&#x02265;39(n=35)</th><th rowspan="1" colspan="1">FSH&#x02265;8.9 and testis length&#x0003c;39 (n=202)</th></tr><tr><th colspan="6" rowspan="1">
<hr/>
</th></tr><tr><td align="left" rowspan="1" colspan="1">Normal spermatogenesis</td><td rowspan="1" colspan="1">127 (30.8)</td><td rowspan="1" colspan="1">11 (21.6)</td><td rowspan="1" colspan="1">97 (78.9)</td><td rowspan="1" colspan="1">13 (37.15)</td><td rowspan="1" colspan="1">6 (3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypo spermatogenesis</td><td rowspan="1" colspan="1">29 (7.1)</td><td rowspan="1" colspan="1">5 (9.8)</td><td rowspan="1" colspan="1">4 (3.3)</td><td rowspan="1" colspan="1">6 (17.15)</td><td rowspan="1" colspan="1">14 (6.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Germ cell maturation arrest</td><td rowspan="1" colspan="1">62 (15.1)</td><td rowspan="1" colspan="1">9 (17.6)</td><td rowspan="1" colspan="1">15 (12.2)</td><td rowspan="1" colspan="1">7 (20)</td><td rowspan="1" colspan="1">31 (15.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Sertoli cell only syndrome</td><td rowspan="1" colspan="1">152 (37)</td><td rowspan="1" colspan="1">19 (37.3)</td><td rowspan="1" colspan="1">4 (3.3)</td><td rowspan="1" colspan="1">5 (14.3)</td><td rowspan="1" colspan="1">124 (61.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Lydig cell hyperplasia</td><td rowspan="1" colspan="1">12 (2.9)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">12 (5.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypo spermatogenesis and maturation arrest (mixed)</td><td rowspan="1" colspan="1">29 (7.1)</td><td rowspan="1" colspan="1">7 (13.7)</td><td rowspan="1" colspan="1">3 (2.4)</td><td rowspan="1" colspan="1">4 (11.4)</td><td rowspan="1" colspan="1">15 (7.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">P value<sup>*</sup></td><td rowspan="1" colspan="1">0.0001</td><td rowspan="1" colspan="1">0.16</td><td rowspan="1" colspan="1">0.0001</td><td rowspan="1" colspan="1">0.015</td><td rowspan="1" colspan="1">0.0001</td></tr><tr><th colspan="6" rowspan="1">
<hr/>
</th></tr></tbody></table><table-wrap-foot><fn><p>Data are presented as n (%). FSH; Follicular stimulating hormone and *
; Analysed with chi-square</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="discussion"><title>Discussion</title><p>Azoospermia is one of the most common male infertility
factors evaluated in various studies (<xref rid="B18" ref-type="bibr">18</xref>). Determination
type of azoospermia helps urologists to treat patients
appropriately. OA patients will undergo reconstructive
surgery if possible. Otherwise, they will undergo sperm
retrieval by testis biopsy for in vitro fertilization/
intracytoplasmic sperm injection (IVF/ICSI). NOA
patients are candidates for sperm retrieval by testis biopsy
(<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B19" ref-type="bibr">19</xref>). If sperm was not found, they are candidates
for sperm donation (<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B21" ref-type="bibr">21</xref>). Several studies show that
azoospermic patients can be correctly sorted into OA
or NOA groups with multiple diagnostic parameters.
Usually, testis volume in OA is normal, whereas in NOA
is less than normal (<xref rid="B7" ref-type="bibr">7</xref>). The results of our study support
this finding significantly. The average testis volume
with an orchidometer in OA is 19.06 ml and in NOA is
10.5 ml. The average testicular long axis measured in
ultrasound for OA is 39.83 mm and for NOA is 33.05
mm. A history of genital infections or epididymo-orchitis
can obstruct an inflammatory process and the production
of antibodies (<xref rid="B22" ref-type="bibr">22</xref>). However, in this study, a history of
epididymo-orchitis or genitourinary system infections
were no significant association with OA or NOA. The
history of an undescended testis (UDT) and orchiopexy is
a risk factor for azoospermia. In fact, UDT is associated
with spermatogenic dysfunction (<xref rid="B23" ref-type="bibr">23</xref>), but findings in the
present study show that the history of UDT and orchiopexy
cannot differentiate OA from NOA. In the absence of
bilateral vas deferens, evaluation of the CFTR panel for
cystic fibrosis is recommended (<xref rid="B24" ref-type="bibr">24</xref>). Our finding similar
to other studies show that lack of bilateral palpation of
vas deferens is associated with OA significantly. In these
patients spermatogenesis is normal and IVF/ICSI can be
used for fertilization (<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B26" ref-type="bibr">26</xref>). Usually, OA patients with
ejaculatory ducts obstruction have semen analysis with
features of low volume, low pH, and low fructose level.
Trans-rectal ultrasound is helpful for the diagnosis of
these patients (<xref rid="B27" ref-type="bibr">27</xref>). The results of this study also confirm
that in OA patients compared to NOA, the mean semen
parameters, including volume, pH, and fructose are
significantly lower than normal. NOA includes primary
testicular failure (high serum FSH with small testis
size), secondary testicular failure (low serum FSH with
small testis size), or incomplete features such as elevated
FSH with normal testis, small testis with normal FSH,
and normal testis with normal FSH. Maturation arrest
histopathology is associated with normal serum FSH and
normal testis size, while Sertoli cell only histopathology
is associated with high serum FSH and small testis size
(<xref rid="B28" ref-type="bibr">28</xref>). The results of our study also confirm this finding,
since the most common pathology in NOA with normal
serum FSH and normal testis size was maturation arrest
and the most common pathology in NOA with high serum
FSH and small testis size was Sertoli cell only.</p><p>According to Schoor et al. (<xref rid="B16" ref-type="bibr">16</xref>) study, differentiating
with high accuracy between OA and NOA is possible by
a combination of serum FSH and testis size. Their results
showed that mean serum FSH, LH, and testosterone levels
in NOA were significantly higher than OA. According to
the results of this study, similar to Schoor&#x02019;s study data,
the mean serum FSH and LH in NOA were significantly
higher than OA, however, the mean serum testosterone
in NOA was significantly lower than OA which is in
contrast with Schoor's results. Based on the ROC curve in
this study, similar to Schoor et al. (<xref rid="B16" ref-type="bibr">16</xref>) and Huang&#x02019;s study
(<xref rid="B29" ref-type="bibr">29</xref>), serum FSH level and testis size have been identified
as the best criteria for predicting the differentiation of OA
from NOA. The best serum FSH level cut off points for
differentiating OA from NOA was 7.6 mIU/ml (sensitivity
77%) in Schoor&#x02019;s study, 9.2 mIU/ml (sensitivity 89%) in
Huang&#x02019;s study, and 8.9 mIU/ml (sensitivity 85%) in the
present study. The best testicular long axis cut off point
for differentiating OA from NOA were 46 mm (sensitivity
72%) in Schoor&#x02019;s study and 39 mm (sensitivity of 83%) in
our study. This discrepancy between testicular long axis
cut off points is likely due to ethnic and racial differences.
For example, testis size in Asian races was significantly
smaller than in Caucasians (<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>). Azoospermic
patients with testicular long axis lower than cut off point
and serum FSH level higher than cut off point, based on
Schoor&#x02019;s study (89% probability), Huang's study (99%
probability), and our study (97% probability) are in NOA
group. Azoospermic patients with testicular long axis
greater than cut off point and serum FSH level lower than
cut off point, based on Schoor&#x02019;s study (96% probability), Huang's study (81% probability), and our study (78%
probability) are in OA group.</p><p>The role of diagnostic testicular biopsy in these patients
is questionable. According to Shoor&#x02019;s study in the
Campbell-Walsh-Wein urology textbook (<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B32" ref-type="bibr">32</xref>), patients
with a high level of serum FSH and small testis size are
NOA with 89% probability. These patients are candidates
for mTESE and IVF/ICSI or sperm cryopreservation
without diagnostic testicular biopsy. However, due to the
impossibility of using sperm donation in some centers
such as our center, a diagnostic testicular biopsy to find
sperm for cryopreservation is recommended with our
team. Then, if sperm are found, their female partners
are candidates for IVF/ICSI. Therefore, inappropriate
treatment costs and medical complications for the patient&#x02019;s
female partners are reduced. Also, according to Shoor&#x02019;s
study, patients who have low serum FSH and normal
testis size are in the OA group with 96% probability.
These patients are candidates for reconstructive surgery
or testis biopsy and sperm extraction alone depending
on their reproductive goals. According to our results,
23.6% of patients in the OA group did not have serum
FSH levels less than 8.9 mIU/ml and a long testicular
axis of more than 39 mm. If a diagnostic testicular biopsy
is not performed in this group of OA patients, they may
be misclassified in the NOA group and are candidates
for mTESE with ICSI, which increases related risks of
ovulation induction for patients&#x02019; female partners and also
wastes unnecessary treatment costs. On the other hand,
21.1% of patients with serum FSH levels less than 8.9
mIU/ml and a long testicular axis of more than 39 mm
were in the NOA group. If a diagnostic testicular biopsy
is not performed in this group of NOA patients, they
may be misclassified in the OA group and are candidates
for reconstructive microsurgery or are recommended
for MESA or TESA with ICSI. Therefore, diagnostic
testicular biopsy seems to be necessary for patients with
OA and NOA characteristics.</p><p>This study has several limitations. First, we did not evaluate mTESE results of NOA
patients with negative TESE. Second, since the spermatogenesis is not uniform in the testis
and it could be patchy so the single testis biopsy cannot show the whole pattern of the
spermatogenesis. Third, data of some patients were incomplete and we had to exclude these
patients from the study.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>In Iranian patients, azoospermic patients are predictable
by the higher level of serum FSH than 8.9 mIU/ml as
well as testicular long axis lower than 39 mm with 97%
probability in NOA group. Azoospermic patients with
serum FSH levels lower than 8.9 mIU/ml and testicular
long axis greater than 39 mm with 78% probability in
the OA group are also predictable. Findings in this study
also emphasize the need for adjusting cut off points based
on patients' ethnicity and race to improve diagnosis.
In addition, diagnostic testicular biopsy seems to be
necessary for patients with OA and NOA characteristics.</p></sec></body><back><ack><title>Acknowledgements</title><p>The authors would like to thank Dr. Goodarzian for
providing photomicrographs describing the pathological
report. We thank all individuals who provided help in this
study, especially the Royan Institute staff. There is no
financial support associated with this study. The authors
declare no conflict of interest. </p></ack><bio id="d64e820"><title>Authors&#x02019; Contributions</title><p>I.S.; Participated in study design, data collection, evaluation,
and interpretation of data. S.M.K.; Participated in study
design and interpretation of data. A.V.T.D.; Participated in
testicular ultrasound and data collection related to testicular
size. T.H.; Participated in the collection, interpretation of
data, and drafting the manuscript. A.R.D.; Participated in the
pathological data gathering and statistical analysis. M.A.S.G.;
Participated in both study design and interpretation of data,
and was responsible for overall supervision. All authors read
and approved the final manuscript.</p></bio><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Venkatesh</surname><given-names>T</given-names></name>
<name><surname>Suresh</surname><given-names>PS</given-names></name>
<name><surname>Tsutsumi</surname><given-names>R</given-names></name>
</person-group><article-title>New insights into the genetic basis of infertility</article-title><source>Appl Clin Genet</source><year>2014</year><volume>7</volume><fpage>235</fpage><lpage>243</lpage><pub-id pub-id-type="pmid">25506236</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ghuman</surname><given-names>N</given-names></name>
<name><surname>Ramalingam</surname><given-names>M</given-names></name>
</person-group><article-title>Male infertility</article-title><source>Obstet Gynaecol Reprod Med</source><year>2018</year><volume>28</volume><issue>1</issue><fpage>7</fpage><lpage>14</lpage></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jequier</surname><given-names>AM</given-names></name>
</person-group><article-title>Semen analysis: a new manual and its application to the understanding of semen and its pathology</article-title><source>Asian J Urol</source><year>2010</year><volume>12</volume><issue>1</issue><fpage>11</fpage><lpage>11</lpage></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gudeman</surname><given-names>SR</given-names></name>
<name><surname>Townsend</surname><given-names>B</given-names></name>
<name><surname>Fischer</surname><given-names>K</given-names></name>
<name><surname>Walters</surname><given-names>RC</given-names></name>
<name><surname>Crain</surname><given-names>D</given-names></name>
</person-group><article-title>Etiology of azoospermia in a military population</article-title><source>J Urol</source><year>2015</year><volume>193</volume><issue>4</issue><fpage>1318</fpage><lpage>1321</lpage><pub-id pub-id-type="pmid">25444960</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nieschlag</surname><given-names>E</given-names></name>
<name><surname>Lenzi</surname><given-names>A</given-names></name>
</person-group><article-title>The conventional management of male infertility</article-title><source>Int J Gynecol</source><year>2013</year><volume>123</volume><fpage>S31</fpage><lpage>35</lpage></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kumar</surname><given-names>N</given-names></name>
<name><surname>Choudhari</surname><given-names>AR</given-names></name>
<name><surname>Singh</surname><given-names>AK</given-names></name>
</person-group><article-title>Prevalence of male factor infertility in last ten years at a rural tertiary care centre of central India: a retrospective analysis</article-title><source>Indian J Obstet Gynecol Res</source><year>2015</year><volume>2</volume><issue>3</issue><fpage>132</fpage><lpage>136</lpage></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yoon</surname><given-names>YE</given-names></name>
<name><surname>Lee</surname><given-names>HH</given-names></name>
<name><surname>Park</surname><given-names>SY</given-names></name>
<name><surname>Moon</surname><given-names>HS</given-names></name>
<name><surname>Kim</surname><given-names>DS</given-names></name>
<name><surname>Song</surname><given-names>SH</given-names></name>
<etal/>
</person-group><article-title>The role of vasoepididymostomy for treatment of obstructive azoospermia in the era of in vitro fertilization: a systematic review and meta-analysis</article-title><source>Asian J Androl</source><year>2018</year><volume>21</volume><issue>1</issue><fpage>67</fpage><lpage>73</lpage></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wosnitzer</surname><given-names>MS</given-names></name>
<name><surname>Goldstein</surname><given-names>M</given-names></name>
</person-group><article-title>Obstructive azoospermia</article-title><source>Urol Clin North Am</source><year>2014</year><volume>41</volume><issue>1</issue><fpage>83</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">24286769</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wosnitzer</surname><given-names>M</given-names></name>
<name><surname>Goldstein</surname><given-names>M</given-names></name>
<name><surname>Hardy</surname><given-names>MP</given-names></name>
</person-group><article-title>Review of azoospermia</article-title><source>Spermatogenesis</source><year>2014</year><volume>4</volume><fpage>e28218</fpage><lpage>e28218</lpage><pub-id pub-id-type="pmid">25105055</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ezeh</surname><given-names>UI</given-names></name>
</person-group><article-title>Beyond the clinical classification of azoospermia: opinion</article-title><source>Hum Reprod</source><year>2000</year><volume>15</volume><issue>11</issue><fpage>2356</fpage><lpage>1259</lpage><pub-id pub-id-type="pmid">11056132</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Akhondi</surname><given-names>MM</given-names></name>
<name><surname>Sedighi</surname><given-names>MA</given-names></name>
<name><surname>Amirjannati</surname><given-names>N</given-names></name>
<name><surname>Sadri-Ardekani</surname><given-names>H</given-names></name>
</person-group><article-title>Use of spermatide for treatment of non-obstructive azoospermic patients</article-title><source>J Reprod Infertil</source><year>2003</year><volume>4</volume><issue>3</issue></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cocuzza</surname><given-names>M</given-names></name>
<name><surname>Alvarenga</surname><given-names>C</given-names></name>
<name><surname>Pagani</surname><given-names>R</given-names></name>
</person-group><article-title>The epidemiology and etiology of azoospermia</article-title><source>Clinics (Sao Paulo)</source><year>2013</year><volume>68</volume><issue>Suppl 1</issue><fpage>15</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">23503951</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Franco</surname><given-names>G</given-names></name>
<name><surname>Scarselli</surname><given-names>F</given-names></name>
<name><surname>Casciani</surname><given-names>V</given-names></name>
<name><surname>De Nunzio</surname><given-names>C</given-names></name>
<name><surname>Dente</surname><given-names>D</given-names></name>
<name><surname>Leonardo</surname><given-names>C</given-names></name>
<etal/>
</person-group><article-title>A novel stepwise micro-TESE approach in non obstructive azoospermia</article-title><source>BMC Urol</source><year>2016</year><volume>16</volume><issue>1</issue><fpage>20</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">27176005</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Coward</surname><given-names>RM</given-names></name>
<name><surname>Mills</surname><given-names>JN</given-names></name>
</person-group><article-title>A step-by-step guide to office-based sperm retrieval for obstructive azoospermia</article-title><source>Transl Androl Urol</source><year>2017</year><volume>6</volume><issue>4</issue><fpage>730</fpage><lpage>744</lpage><pub-id pub-id-type="pmid">28904906</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jungwirth</surname><given-names>A</given-names></name>
<name><surname>Giwercman</surname><given-names>A</given-names></name>
<name><surname>Tournaye</surname><given-names>H</given-names></name>
<name><surname>Diemer</surname><given-names>T</given-names></name>
<name><surname>Kopa</surname><given-names>Z</given-names></name>
<name><surname>Dohle</surname><given-names>G</given-names></name>
<etal/>
</person-group><article-title>european association of urology guidelines on male infertility: the 2012 update</article-title><source>Eur Urol</source><year>2012</year><volume>62</volume><issue>2</issue><fpage>324</fpage><lpage>332</lpage><pub-id pub-id-type="pmid">22591628</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schoor</surname><given-names>RA</given-names></name>
<name><surname>Elhanbly</surname><given-names>S</given-names></name>
<name><surname>Niederberger</surname><given-names>CS</given-names></name>
<name><surname>Ross</surname><given-names>LS</given-names></name>
</person-group><article-title>The role of testicular biopsy in the modern management of male infertility</article-title><source>J Urol</source><year>2002</year><volume>167</volume><issue>1</issue><fpage>197</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">11743304</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Unal</surname><given-names>I</given-names></name>
</person-group><article-title>Defining an optimal cut-point value in ROC analysis: an alternative approach</article-title><source>Comput Math Methods Med</source><year>2017</year><volume>2017</volume><fpage>3762651</fpage><lpage>3762651</lpage><pub-id pub-id-type="pmid">28642804</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Agarwal</surname><given-names>A</given-names></name>
<name><surname>Panner Selvam</surname><given-names>MK</given-names></name>
<name><surname>Baskaran</surname><given-names>S</given-names></name>
<name><surname>Finelli</surname><given-names>R</given-names></name>
<name><surname>Leisegang</surname><given-names>K</given-names></name>
<name><surname>Barb&#x00103;ro&#x0015f;ie</surname><given-names>C</given-names></name>
<etal/>
</person-group><article-title>A scientometric analysis of research publications on male infertility and assisted reproductive technology</article-title><source>Andrologia</source><year>2021</year><volume>53</volume><issue>1</issue><fpage>e13842</fpage><lpage>e13842</lpage><pub-id pub-id-type="pmid">33236365</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shah</surname><given-names>R</given-names></name>
<name><surname>Gupta</surname><given-names>C</given-names></name>
</person-group><article-title>Advances in sperm retrieval techniques in azoospermic men: a systematic review</article-title><source>Arab J Urol</source><year>2017</year><volume>16</volume><issue>1</issue><fpage>125</fpage><lpage>131</lpage><pub-id pub-id-type="pmid">29713543</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><collab>Brugh VM 3rd, Lipshultz LI</collab><article-title>Male factor infertility: evaluation and management</article-title><source>Med Clin North Am</source><year>2004</year><volume>88</volume><issue>2</issue><fpage>367</fpage><lpage>385</lpage><pub-id pub-id-type="pmid">15049583</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>J</given-names></name>
<name><surname>Yap</surname><given-names>C</given-names></name>
</person-group><article-title>Embryo donation: a review</article-title><source>Acta Obstet Gynecol Scand</source><year>2003</year><volume>82</volume><issue>11</issue><fpage>991</fpage><lpage>996</lpage><pub-id pub-id-type="pmid">14616271</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pilatz</surname><given-names>A</given-names></name>
<name><surname>Kilb</surname><given-names>J</given-names></name>
<name><surname>Kaplan</surname><given-names>H</given-names></name>
<name><surname>Fietz</surname><given-names>D</given-names></name>
<name><surname>Hossain</surname><given-names>H</given-names></name>
<name><surname>Sch&#x000fc;ttler</surname><given-names>CG</given-names></name>
<etal/>
</person-group><article-title>High prevalence of urogenital infection/inflammation in patients with azoospermia does not impede surgical sperm retrieval</article-title><source>Andrologia</source><year>2019</year><volume>51</volume><issue>10</issue><fpage>e13401</fpage><lpage>e13401</lpage><pub-id pub-id-type="pmid">31456226</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Caroppo</surname><given-names>E</given-names></name>
<name><surname>Niederberger</surname><given-names>C</given-names></name>
<name><surname>Elhanbly</surname><given-names>S</given-names></name>
<name><surname>Schoor</surname><given-names>R</given-names></name>
<name><surname>Ross</surname><given-names>L</given-names></name>
<name><surname>D'Amato</surname><given-names>G</given-names></name>
</person-group><article-title>Effect of cryptorchidism and retractile testes on male factor infertility: a multicenter, retrospective, chart review</article-title><source>Fertil Steril</source><year>2005</year><volume>83</volume><issue>5</issue><fpage>1581</fpage><lpage>1584</lpage><pub-id pub-id-type="pmid">15866613</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McCallum</surname><given-names>T</given-names></name>
<name><surname>Milunsky</surname><given-names>J</given-names></name>
<name><surname>Munarriz</surname><given-names>R</given-names></name>
<name><surname>Carson</surname><given-names>R</given-names></name>
<name><surname>Sadeghi-Nejad</surname><given-names>H</given-names></name>
<name><surname>Oates</surname><given-names>R</given-names></name>
</person-group><article-title>Unilateral renal agenesis associated with congenital bilateral absence of the vas deferens: phenotypic findings and genetic considerations</article-title><source>Hum Reprod</source><year>2001</year><volume>16</volume><issue>2</issue><fpage>282</fpage><lpage>288</lpage><pub-id pub-id-type="pmid">11157821</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Esteves</surname><given-names>SC</given-names></name>
<name><surname>Lee</surname><given-names>W</given-names></name>
<name><surname>Benjamin</surname><given-names>DJ</given-names></name>
<name><surname>Seol</surname><given-names>B</given-names></name>
<name><surname>Verza S</surname><given-names>Jr</given-names></name>
<name><surname>Agarwal</surname><given-names>A</given-names></name>
</person-group><article-title>Reproductive potential of men with obstructive azoospermia undergoing percutaneous sperm retrieval and intracytoplasmic sperm injection according to the cause of obstruction</article-title><source>J Urol</source><year>2013</year><volume>189</volume><issue>1</issue><fpage>232</fpage><lpage>237</lpage><pub-id pub-id-type="pmid">23174251</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Janzen</surname><given-names>N</given-names></name>
<name><surname>Goldstein</surname><given-names>M</given-names></name>
<name><surname>Schlegel</surname><given-names>PN</given-names></name>
<name><surname>Palermo</surname><given-names>GD</given-names></name>
<name><surname>Rosenwaks</surname><given-names>Z</given-names></name>
<name><surname>Hariprashad</surname><given-names>J</given-names></name>
</person-group><article-title>Use of electively cryopreserved microsurgically aspirated epididymal sperm with IVF and intracytoplasmic sperm injection for obstructive azoospermia</article-title><source>Fertil Steril</source><year>2000</year><volume>74</volume><issue>4</issue><fpage>696</fpage><lpage>701</lpage><pub-id pub-id-type="pmid">11020509</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Modgil</surname><given-names>V</given-names></name>
<name><surname>Rai</surname><given-names>S</given-names></name>
<name><surname>Ralph</surname><given-names>DJ</given-names></name>
<name><surname>Muneer</surname><given-names>A</given-names></name>
</person-group><article-title>An update on the diagnosis and management of ejaculatory duct obstruction</article-title><source>Nat Rev Urol</source><year>2016</year><volume>13</volume><issue>1</issue><fpage>13</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">26620608</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gonsalves</surname><given-names>J</given-names></name>
<name><surname>Sun</surname><given-names>F</given-names></name>
<name><surname>Schlegel</surname><given-names>PN</given-names></name>
<name><surname>Turek</surname><given-names>PJ</given-names></name>
<name><surname>Hopps</surname><given-names>CV</given-names></name>
<name><surname>Greene</surname><given-names>C</given-names></name>
<etal/>
</person-group><article-title>Defective recombination in infertile men</article-title><source>Hum Mol Genet</source><year>2004</year><volume>13</volume><issue>22</issue><fpage>2875</fpage><lpage>2883</lpage><pub-id pub-id-type="pmid">15385442</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>IS</given-names></name>
<name><surname>Huang</surname><given-names>WJ</given-names></name>
<name><surname>Lin</surname><given-names>AT</given-names></name>
</person-group><article-title>Distinguishing non-obstructive azoospermia from obstructive azoospermia in Taiwanese patients by hormone profile and testis size</article-title><source>J Chin Med Assoc</source><year>2018</year><volume>81</volume><issue>6</issue><fpage>531</fpage><lpage>535</lpage><pub-id pub-id-type="pmid">29079114</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kuiri-H&#x000e4;nninen</surname><given-names>T</given-names></name>
<name><surname>Seuri</surname><given-names>R</given-names></name>
<name><surname>Tyrv&#x000e4;inen</surname><given-names>E</given-names></name>
<name><surname>Turpeinen</surname><given-names>U</given-names></name>
<name><surname>H&#x000e4;m&#x000e4;l&#x000e4;inen</surname><given-names>E</given-names></name>
<name><surname>Stenman</surname><given-names>UH</given-names></name>
<etal/>
</person-group><article-title>Increased activity of the hypothalamic-pituitary- testicular axis in infancy results in increased androgen action in premature boys</article-title><source>J Clin Endocrinol Metab</source><year>2011</year><volume>96</volume><issue>1</issue><fpage>98</fpage><lpage>105</lpage><pub-id pub-id-type="pmid">20881260</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thankamony</surname><given-names>A</given-names></name>
<name><surname>Pasterski</surname><given-names>V</given-names></name>
<name><surname>Ong</surname><given-names>KK</given-names></name>
<name><surname>Acerini</surname><given-names>CL</given-names></name>
<name><surname>Hughes</surname><given-names>IA</given-names></name>
</person-group><article-title>Anogenital distance as a marker of androgen exposure in humans</article-title><source>Andrology</source><year>2016</year><volume>4</volume><issue>4</issue><fpage>616</fpage><lpage>625</lpage><pub-id pub-id-type="pmid">26846869</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Wein</surname><given-names>AJ</given-names></name>
<name><surname>kavoussi</surname><given-names>LR</given-names></name>
<name><surname>Partin</surname><given-names>AW</given-names></name>
<name><surname>Peters</surname><given-names>CA</given-names></name>
</person-group><source>Campbell Walsh urology</source><edition>12th ed</edition><publisher-loc>Philadelphia, USA</publisher-loc><publisher-name>Elsevier</publisher-name><year>2021</year><size units="page">1447</size></element-citation></ref></ref-list></back></article>
